With the Federal Reserve standing pat this week, the S&P 500 index has reached another all-time high.
Yet this bull market is proving to be even more fertile for investors in small-cap and micro-cap stocks. Both the iShares Russell Microcap Index and the Russell 2000 Small Cap Index are outperforming the S&P 500 by a solid margin over the past two years.
With no end in sight to the bull market, there's no reason to stop focusing on these small companies at this juncture. If the economy can manage to build a head of steam in 2014 and 2015, then these small stocks should see even deeper investor interest.
Here are three stocks that all trade below $5 and sport market values below $500 million -- and are poised for solid upside if this rally continues.
1. Lionbridge Technologies (Nasdaq: LIOX) I took note of heavy insider buying at this language translation services firm back in July, and though shares are up nearly 10% since then, the company's outlook has brightened markedly.On the second-quarter conference call, management delivered its most upbeat discussion of business trends in several years, noting that Lionbridge is seeing an expansion in its relationship with Microsoft (Nasdaq: MSFT), the return of several other large tech clients that had dropped off in the past few years, and a rising order book with manufacturing and life sciences clients.
Hot Wireless Telecom Companies To Own For 2015: VCA Antech Inc (WOOF)
VCA Antech, Inc., incorporated on May 4, 1987, is a national animal healthcare company operating in the United States and Canada. The Company provides veterinary services and diagnostic testing to support veterinary cares. The Company operates in two segments: animal hospital and laboratory. Its all other category includes Vetstreet and Medical Technology operating segments. The Company sells diagnostic imaging equipment and other medical technology products and related services to the veterinary markets. The Company's animal hospitals offer a range of general medical and surgical services for companion animals, as well as specialized treatments, including advanced diagnostic services, internal medicine, oncology, ophthalmology, dermatology and cardiology. On January 31, 2012, it expanded its operations into Canada with an increased investment in Associate Veterinary Clinics (1984) Limited (AVC), which operates 44 hospitals in three Canadian provinces. On February 1, 2012, it acquired ThinkPet's, Inc. (ThinkPets). In 2012, it acquired 79 animal hospitals, including 44 with the acquisition of AVC, one laboratory and ThinkPets.
The Company provides various communication, marketing solutions and other services to the veterinary community. The Company's network of animal hospitals is supported by more than 3,000 veterinarians and had approximately 7.4 million patient visits during the year ended December 31, 2012. The Company's network of veterinary diagnostic laboratories provides testing and consulting services used by veterinarians in the detection, diagnosis, evaluation, monitoring, treatment and prevention of diseases and other conditions affecting animals. The Company's network of veterinary diagnostic laboratories provides diagnostic testing for over 16,000 clients, which includes standard animal hospitals, large animal practices, universities and other government organizations. The Company's medical technology business sells digital radiography and ultrasound imaging equipment, provid! es education and training on the use of that equipment, and provides consulting and mobile imaging services.
The Company's Vetstreet business provides services to veterinary practices, pharmaceutical manufacturers, and the pet owning community. The Company's services to veterinary practices include subscriptions to the Company's Pro Pet Portals. The Pro Pet Portal provides an online platform for the veterinarian to offer secure individualized portals for pet owners, as well as practice Websites that are branded to the individual veterinary clinic. The Company also sells appointment reminder notices that are sent to pet owners on behalf of their clinics. The Company's services to manufacturers involve targeted marketing programs to animal hospitals whom are subscribers to the Company's Pro Pet Portal.
Animal Hospital
As of December 31, 2012, the Company operated 609 animal hospitals serving 41 states and three Canadian provinces. The Company's Animal Hospital revenue accounted for 78% of total revenue in 2012. In addition to general medical and surgical services, the Company offers specialized treatments for companion animals, including advanced diagnostic services, internal medicine, oncology, ophthalmology, dermatology and cardiology. The Company also provides pharmaceutical products for uses in the delivery of treatments by its veterinarians and pet owners. Many of the Company's animal hospitals offer additional services, including grooming, bathing and boarding. The Company also sells specialty pet products at its animal hospitals, including pet food, vitamins, therapeutic shampoos and conditioners, flea collars and sprays, and other accessory products.
Laboratory
The Company operates a veterinary diagnostic laboratory network serving all 50 states and certain areas in Canada. The Company's Laboratory revenue accounted for 16% of total revenue in 2012. The Company service a diverse customer base of over 16,000 clients, including animal! hospital! s the Company operates, which accounted for 16% of total laboratory revenue in 2012. The Company's diagnostic spectrum includes over 300 different tests in the area of chemistry, pathology, endocrinology, serology, hematology and microbiology, as well as tests specific to particular diseases. As of December 31, 2012, the Company operated 55 veterinary diagnostic laboratories. The Company's laboratory network includes primary hubs that are open 24 hours per day and offer a testing menu, secondary laboratories that are open 24 hours per day and offer a testing menu servicing large metropolitan areas, and short-term assessment and treatment (STAT) laboratories that service other locations with demand sufficient to warrant nearby laboratory facilities and are open primarily during daytime hours. In 2012, the Company derived approximately 85% of its laboratory revenue from metropolitan areas, where the Company offers twice-a-day pick-up service and same-day results. In addition, in these areas the Company generally offers to report results within three hours of pick-up. Outside of these areas, the Company typically provides test results to veterinarians before 8:00 a.m. the day following pick-up.
The Company competes with IDEXX Laboratories, Demand Force, and ePet Health.
Advisors' Opinion:- [By John Udovich]
About�a week ago, Wall Street was biting small cap pet stock Petmed Express Inc (NASDAQ: PETS) for not living up to its earnings expectations�- meaning it might be worth taking a closer look at the stock�and compare its performance with other pet stocks like mid cap PetSmart, Inc (NASDAQ: PETM) and small cap VCA Antech Inc (NASDAQ: WOOF). I should also mention that we have recently added Petmed Express to our SmallCap Network Elite Opportunity (SCN EO) portfolio because we think the stock is undervalued in the pet space and has tremendous growth potential�moving forward.
- [By Sean Williams]
Let's also not forget about the physical surgical and veterinary centers themselves. VCA Antech (NASDAQ: WOOF ) , for instance, operates more than 600 hospitals around the U.S., as well as 55 diagnostic laboratories. Like PetSmart, VCA hasn't seen a decline in revenue in any of the past 10 years, growing sales by 212% over that timespan thanks to growth in services rendered, ample pricing power, and strong ancillary sales of premium food and vitamins from its hospitals and veterinary centers.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on VCA Antech (Nasdaq: WOOF ) , whose recent revenue and earnings are plotted below.
Hot Life Sciences Stocks To Watch For 2014: Terra Catalyst Fund (TCF)
Terra Catalyst Fund is a closed-end investment fund. The Company's investment objective and policy is to seek realization of its portfolio of investments in the ordinary course of business and, subject to retaining sufficient cash to meet operating costs and liabilities, to return the net proceeds of all such realizations to Shareholders on a periodic basis, following which the Company will be wound-up. The investment manager of the Company is Laxey Partners Limited. Advisors' Opinion:- [By Rustic Nomad]
Analyst Jiang, on the other hand, is seeing good pace in gas storage, exiting the summer at about 0.05 trillion cubic feet (Tcf), which is 0.8 Tcf below the normal and is on track to match the lowest winter exit for storage inventories since 2004.
Hot Life Sciences Stocks To Watch For 2014: Imprimis Pharmaceuticals Inc (IMMY)
Imprimis Pharmaceuticals Inc. is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company�� Transdel cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel, the Company�� lead pain product, utilizes the Transdel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its anti-inflammatory and analgesic effects. Ketotransdel consists of a transdermal formulation of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), and its Transdel drug delivery system and is being developed for the treatment of acute pain. In July 2013, it acquired intellectual property for IPI-120 from Buderer Drug Company.
Ketotransdel penetrates the skin barrier to reach the targeted underlying tissues where it exerts its localized anti-inflammatory and analgesic effect. Transdel is the Company�� transdermal cream drug delivery platform. It consists of a cream that enables transdermal penetration of drugs avoiding first pass metabolism by the liver and minimizing systemic exposure. The Transdel drug delivery system facilitates the effective dissolution and delivery of a drug across the skin barrier to reach targeted underlying tissues.
Advisors' Opinion:- [By John Udovich]
The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:
Hot Life Sciences Stocks To Watch For 2014: Banco Santiago S.A.(SAN)
Banco Santander-Chile provides commercial and retail banking services to corporate and individual customers in Chile. The company offers time and demand deposits, checking accounts, and debit card accounts, as well as savings products; and peso and foreign currency denominated loans to finance various commercial transactions, trade, foreign currency forward contracts, and credit lines. Its loan portfolio comprises consumer loans, auto loans, residential mortgage loans, mutual funds, foreign trade financing, mortgage loans, and commercial loans. The company also provides factoring, credit cards, cash management, treasury services, short?term financing and funding, interest rate and foreign currency derivatives, and securitization services. Further, it offers various financial services, including leasing, financial leasing, financial advisory, mutual fund management, securities brokerage, insurance brokerage, and investment management services. As of December 31, 2010, the company had a branch network of 504 branches. Banco Santander-Chile was founded in 1977 and is headquartered in Santiago, Chile.
Advisors' Opinion:- [By fedezaldua]
Santander�(SAN)'s dividend yield, at an expected 9%, is the highest among large banking institutions, but its payout ratio is as high as it gets at an expected 119% for 2014 ��down from 132% in 2013. As a matter of fact, I would not expect the bank to have a dividend payout ratio below 100% until 2016. Nevertheless, the bank's chairman ��Emilio Botin ��is very much committed to sustaining Santander's dividend and we should not expect this policy to change in the foreseeable future unless the Bank of Spain forbids Santander to keep on distributing cash at the current rate.
- [By Dan Burrows]
It also pays to be a little patient with Inland while waiting for price appreciation. Like the broader market, IRC stock was bound to cool off after such a strong run in 2013.
Cheap Dividend Stocks #4: Banco Santander (SAN)Share Price as of 4/4: $9.93
YTD Stock Performance: 9%
Dividend Yield: 6.4%
Hot Life Sciences Stocks To Watch For 2014: Rolls-Royce Holdings PLC (RYCEY)
Rolls-Royce Holdings plc, formerly Rolls-Royce Group plc is a provider of power systems and services for use on land, at sea and in the air. The Company operates in four segments: civil aerospace, defense aerospace, marine and energy. The civil aerospace is engaged in development, manufacture, marketing and sales of commercial aero engines and aftermarket services. The defense aerospace is engaged in development, manufacture, marketing and sales of military aero engines and aftermarket services. The marine segment is engaged in development, manufacture, marketing and sales of marine propulsion systems and aftermarket services. The energy segment is engaged in development, manufacture, marketing and sales of power systems for the offshore oil and gas industry and electrical power generation and aftermarket services. In January 2013, the Company bought PKMJ Technical Services. In January 2013, Alstom SA acquired Tidal Generation Limited from the Company.
During the year ended December 31, 2010, it acquired ODIM ASA. In June 2011, Daimler AG and Rolls-Royce Holdings PLC had secured around 94% interest in Tognum AG-DJ. In September 2011, the Company acquired R Brooks Associates.
Civil aerospace
The Company�� civil aerospace business provides the powers for 30 different types of commercial aircraft in a range of markets, such as widebody, narrowbody, corporate and regional aircraft. As of December 31, 2010, it had over 13,000 engines in service with 650 airlines, freight operators and lessors and 4,000 corporate operators. Its civil aerospace products include large aircraft engines, small aircraft engines and helicopter engines. The Company�� Trent 700 is an engine on the Airbus A330. The Trent 1000 is powering the Boeing 787 on the aircraft�� flight test schedule. It provides a range of services, such as TotalCare, CorporateCare, helicopters services, financial services, training and technical publications.
Defence Aerospace
The Compan! y is a provider of defence aero-engine products and services, with 18,000 engines in service for 160 customers in 103 countries. It is also the supplier of engines for transport aircraft globally, powering fleets, such as the C-130, C-130J, Spartan C-27 and Osprey V-22. It is also involved in research projects, such as Adoptive Versatile Engine Technology (ADVENT), which is designed to reduce fuel consumption. Its engines power aircraft in all sectors, such as transport, combat, reconnaissance, training, helicopters and unmanned aerial vehicles. The defense aerospace segment of the Company provides engines power aircraft in all sectors, such as transport, combat, reconnaissance, training, helicopters and unmanned aerial vehicles. Its products include combat jets, helicopters, transporters, trainers, tactical aircraft, unmanned aerial vehicles and distributed generation systems. It provides a range of services, such as training, technical publications and service locations.
Marine
The Company focuses on power, propulsion and motion control solutions and serves over 2,500 customers and has equipment installed on 30,000 vessels operating worldwide. As of December 31, 2010, the Company had 650 designed and equipped vessels operating in the offshore oil and gas sector. As of December 31, 2010, it had more than 2,500 marine customers and has equipment installed on over 30,000 vessels worldwide, including those of 70 navies. The energy business supplies gas turbines, compressors and diesel power units. Its products include automation and control, bearings and seals, deck machinery, electrical power systems, engines, gears, propulsors, ship design, shiplifts and submarine equipment. It provides a range of services, such as global support network, spares and tools, field shop services, technical support, training, tailored solutions and upgrading.
Energy
The Company is a provider of gas turbines for onshore and offshore applications. The Company�� energy busi! ness is e! ngaged in two activities: supply power to the oil and gas sector, and the provision of power generation products and services. Its products include gas engines, gas turbine engines, gas compression, diesel engines, fuel cells, and automation and control systems. Its services consist of long term service agreements, component supply and technical support, distributed generation systems and training. During the year ended December 31, 2010, it conducted a range of a tidal power turbine, anchored on the sea bed off the coast of Scotland. During 2010, this had generated 500 kilo-watt at full power and has been successfully linked into the national grid.
Advisors' Opinion:- [By CanadianValue]
At Rolls-Royce (RYCEY), new CEO John Rishton had a busy and fruitful start to his tenure. Most importantly, Rishton began to focus Rolls on areas where the company stood to improve, including cash generation, cost structure and customer service. He also successfully extracted the company from its legacy narrow body civil engine joint-venture with Pratt & Whitney (IAE) for an attractive price, positioned Rolls as exclusive supplier for the Airbus A350-1000, further secured the company�� strong position on the A350 program, and closed the tricky Tognum acquisition which will begin to bear fruit in 2012. While Rolls had not released its 2011 results as of the writing of this letter, both we and the markets expect the company to report mid-to-high single digits revenue growth and low-to-mid-teens earnings growth in the year past.
- [By Rich Smith]
The Department of Defense awarded a round dozen defense contracts Friday, worth just under $7.2 billion in aggregate. The bulk of the contracts -- $7 billion worth -- were split among eight small privately held firms scattered around New Jersey, Maryland, Indiana, and Virginia contracted to supply software and systems engineering services in support of the Army's Software Engineering Center. But a handful of better-known -- and, more importantly to investors, publicly traded -- companies won contracts as well. Namely:
- [By Rich Smith]
According to the DSCA, Lockheed Martin (NYSE: LMT ) will be the prime contractor on this sale, which is valued at $588 million. It would involve not only the sale of the planes per se, but also eight Rolls Royce (NASDAQOTH: RYCEY ) AE 2100D3 engines for the four-engine planes, and two spare engines, plus modifications to be made on the planes, radio equipment and other accessories, technical documentation, three years of training, and related logistics services.
Hot Life Sciences Stocks To Watch For 2014: Titan Company Ltd (TITAN)
Titan Company Limited, formerly Titan Industries Limited, is engaged in manufacturing of watches/accessories, jewelry, precision engineering and eyewear. The Company has four divisions: watches/accessories, jewelry, precision engineering and eyewear. As of March 31, 2012, the Company had 332 World of Titan stores. As of March 31, 2012, the Company had over three business units in Bangalore, India, a manufacturing unit at Hosur and three assembly plants located in the north of India. The brands under the watches/accessories division include: Titan, Sonata, Fastrack, Xylys and others. Tanishq is Titan�� line of jewelry with a range of jewelry, studded with diamonds or colored gems in 18-karat gold, 22-karat gold and platinum jewelry. Under eyewear division, there is a brand named Titan Eye plus. The precision engineering division includes machine building and automation solutions and tooling solutions. In March 2013, Titan Properties Ltd. was amalgamated with the Company. Advisors' Opinion:- [By James Miller Phd]
Peers like Microsoft Corp. (MSFT) and Oracle Corp. (ORCL) present strong competition in the could-based CRM market, and have been enhancing their companies through various acquisitions such as recently acquired Nimbula, Eloqua Inc., RightNow Technologies and Taleo Corp from Oracle, or MarketingPilot and Netbreeze from Microsoft. Competition is moreover expected to increase with the introduction of Microsoft Dynamics CRM software (Titan). Nevertheless, Salesforce has also been strengthening its product portfolio and expanding within the cloud based CRM services.
Hot Life Sciences Stocks To Watch For 2014: GenMark Diagnostics Inc.(GNMK)
GenMark Diagnostics, Inc. operates as a molecular diagnostics company primarily in the United States. It focuses on the development and commercialization of multiplexed molecular diagnostic testing systems for the detection and measurement of DNA and RNA targets used in the treatment of patients. The company?s products comprise eSensor XT-8 system, an automated molecular diagnostic system, which enable reference laboratories and hospitals to perform molecular diagnostic tests; and eSensor XT-8 Cartridge that utilizes a microfluidic system to accelerate target binding and enhance time to result. It also offers IVD tests, including eSensor cystic fibrosis genotyping test, eSensor thrombophilia risk test, and eSensor warfarin sensitivity test. The company?s other multiplexed molecular diagnostic tests pipeline under development comprise eSensor 2C19 test for the multiplexed detection and genotyping of various alleles of the cytochrome P450 (CYP450) 2C19 gene locus; eSensor respiratory viral panel, a nucleic acid multiplex test for the simultaneous detection and identification of multiple respiratory virus nucleic acids and mutations that confer resistance of Influenza A to the anti-viral drug Oseltamivir (Tamiflu); and eSensor KRAS/BRAF test for the multiplexed detection and genotyping of 12 mutations in codons 12 and 13 of KRAS and the V600E mutation in BRAF. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Advisors' Opinion:- [By Sean Williams]
What: Shares of GenMark Diagnostics (NASDAQ: GNMK ) , a molecular diagnostics company, slumped as much as 10% after updating its full-year revenue guidance after the bell last night.
- [By Roberto Pedone]
GenMark Diagnostics (GNMK) is a molecular diagnostics company, engages in the development, manufacturing, marketing, sale, and support of instruments and molecular tests based on its proprietary eSensor detection technology in the U.S. This stock closed up 1.7% to $9.89 in Tuesday's trading session.
Tuesday's Range: $9.24-$9.95
52-Week Range: $6.38-$16.00
Thursday's Volume: 562,000
Three-Month Average Volume: 385,008From a technical perspective, GNMK bounced modestly higher here with above-average volume. This stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $8.75 on the downside and $10.71 on the upside. This bounce is starting to push GNMK within range of triggering a near-term breakout trade above the upper-end of its sideways trading chart pattern. That breakout will hit if GNMK manages to clear some near-term overhead resistance levels at $10.04 to $10.50 and then once it takes out more resistance at $10.71 with high volume.
Traders should now look for long-biased trades in GNMK as long as it's trending above Tuesday's low of $9.24 or around $9 and then once it sustains a move or close above those breakout levels with volume that hits near or above 385,008 shares. If that breakout triggers soon, then GNMK will set up to re-test or possibly take out its next major overhead resistance levels at $12 to $13.50.
No comments:
Post a Comment